**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54243

**Manuscript Type:** CASE REPORT

**Early-onset refractory diarrhea due to immune dysregulation, polyendocrinopathy, enteropathy, x-linked** **syndrome** **associated with a novel mutation in the *foxp3* gene: a case report**

Su N *et al*. Novel *FOXP3* gene mutation causing IPEX syndrome

Na Su, Cheng Chen, Xia Zhou, Guo-Da Ma, Ri-Ling Chen, Chuan Tian

**Na Su,** Department of Pediatrics, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

**Cheng Chen,** **Ri-Ling Chen,** Department of Pediatric Internal Medicine, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan 528300, Guangdong Province, China

**Xia Zhou,** Department of Neurology, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

**Guo-Da Ma,** Maternal and Child Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan 528300, Guangdong Province, China

**Chuan Tian,** Department of Pediatric Hematology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

**Author contributions:** Su N, Ma GD, and Zhou X reviewed the literature, contributed to drafting of the manuscript, and prepared the figures and table; Chen C, Chen RL, and Tian C discussed the diagnosis and treatment; all authors issued final approval for the version to be submitted.

**Corresponding author:****Ri-Ling Chen, MD, Professor,** Department of Pediatric Internal Medicine, Shunde Women and Children's Hospital, Guangdong Medical University, No. 3, Baojian Road, Foshan 528300, Guangdong Province, China. chenrl319@163.com

**Received:** January 16, 2020

**Revised:** April 1, 2020

**Accepted:** April 21, 2020

**Published online:**

**Abstract**

BACKGROUND

Immune dysregulation, polyendocrinopthy, enteropathy, X-linked (IPEX) syndrome is a rare X-linked recessive disease caused by mutations in the forkhead box protein 3 (*FOXP3*)gene, which is a master transcriptional regulator for the development and function of CD4+CD25+ regulatory T (Treg) cells. The dysfunction of these cells leads to multiple system autoimmune diseases. We present a case of IPEX due to a mutation not reported in the literature before.

### CASE SUMMARY

We report a male patient with IPEX syndrome who presented with refractory diarrhea and malabsorption leading to failure to thrive, as well as with hypothyroidism and nephrotic syndrome. Laboratory investigation showed increased total IgE and Treg cells, decreased free triiodothyronine (FT3) and free thyroxine (FT4), and proteinuria. Multiple dietary and supportive treatments were introduced but did not improve the diarrhea during his hospital stay. Ultimately, whole exome sequencing revealed that the patient was hemizygous for the exon 5, c.542G>A (p.Ser181Asn) mutation of the *FOXP3* gene, which has not been previously reported. The patient remains on prednisone and euthyrox while awaiting hematopoietic stem cell transplantation at the time of the compilation of this case report.

CONCLUSION

We report a novel *FOXP3* gene mutation involved in IPEX. A high level of suspicion should be maintained in an early-onset refractory diarrhea patient.

**Key words:** Immune dysregulation, polyendocrinopthy, enteropathy, x-linked syndrome; Forkhead box protein 3; Mutation; Refractory diarrhea; Regulatory T cells; Case report

Su N, Chen C, Zhou X, Ma GD, Chen RL, Tian C. Early-onset refractory diarrhea due to immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome associated with a novel mutation in the *FOXP3* gene: A case report. *World J Clin Cases* 2020; In press

**Core tip:**Immune dysregulation, polyendocrinopthy, enteropathy, X-linked syndrome is a rare X-linked recessive disease caused by mutations in the *FOXP3* gene. Patients most commonly present symptoms with refractory diarrhea, type 1 diabetes mellitus, eczema, and rarely, symptoms of nephrotic syndrome, hypothyroidism, and thrombocytopenia. Herein, we present a patient with refractory diarrhea, failure to thrive, hypothyroidism, and nephrotic syndrome who was subsequently found to have a novel mutation in the *FOXP3* gene [c.542G>A (p.Ser181Asn)]. Patients with immune dysregulation, polyendocrinopthy, enteropathy, X-linked generally require supportive treatments and replacement therapy, such as steroids, immunosuppressors, or hematopoietic stem cell transplantation.

**INTRODUCTION**

Immune dysregulation, polyendocrinopthy, enteropathy, X-linked (IPEX) syndrome is a rare disorder of genetic autoimmunity caused by mutations in the forkhead box protein 3 *(FOXP3)* gene[1]. FOXP3is an important transcription regulator in the development of CD4+CD25+ regulatory T (Treg) cells. *FOXP3* gene mutations lead to developmental defects, differentiation disorders, and dysfunction of Tregs, which lead to serious autoimmune phenomena in multiple systems[2]. The disease mainly influences the intestine, endocrine system, and skin[2], whereas the thyroid glands, kidneys, blood cells, liver, and joints may also be influenced[3]. IPEX is an X-linked recessive disorder, and patients who have not been treated effectively in the early stage mostly die within 2 years of age[4]. The main treatment measures for patients with IPEX include supportive care, immunosuppressive treatments, and hematopoietic stem cell transplantation. The clinical manifestations of the disease were first reported in 1982 by Powell *et al*[5], and an increasing number of cases were subsequently reported. Here, we report a male patient with IPEX syndrome who had refractory diarrhea, failure to thrive, hypothyroidism, and nephrotic syndrome and who was hemizygous in the *FOXP3* gene [c.542G>A (p.Ser181Asn)].

**CASE PRESENTATION**

***Chief complaints***

A 13-month-old male patient was admitted to the hospital in June 2019 due to chronic diarrhea and malnutrition.

***History of present illness***

The patient’s symptoms started a year ago with recurrent diarrhea and malnutrition. His diarrhea had been worsened the last 4 h (10 watery bowel movements).

***Personal and family history***

The patient is the second live-born child of nonconsanguineous and healthy parents (Figure 1) and was born at 35 wk of gestation by spontaneous vaginal delivery. The newborn had a birth weight of 2.15 kg and was hospitalized as a premature infant. The family history was negative for inherent diseases.

***History of past illness***

At the age of 1 mo, the patient had refractory diarrhea (up to 10-15 watery bowel movements per day) and scattered eczema. Therefore, he was hospitalized on several occasions at a local hospital and given hydrolyzing protein formula milk and supportive care to improve gastrointestinal symptoms. The eczema gradually disappeared in May after birth, but diarrhea did not significantly improve.

***Physical examination***

Upon admission to the hospital, the patient had a weight of 6.4 kg, head circumference of 40.5 cm, and length 70 cm, failure to thrive, and moderate-severe dehydration. Abdominal subcutaneous fat thickness was less than 4 mm, and bowel sounds were active, approximately 7 per minute.

***Laboratory examinations***

The laboratory results showed a normal eosinophil count and hemoglobin concentration; a high white blood cell count (23.25 × 109/L); normal immunoglobulin A, IgG, and IgM levels but markedly elevated IgE levels (1970 IU/mL); high triglyceride (3.74 mmol/L); and decreased complement C3 (0.25 g/L), complement C4 (0.1 g/L), and albumin (29.1 g/L). The endocrine test showed normal antithyroid peroxidase (aTPO), antithyroglobulin (aTG), and thyroid stimulating hormone (TSH), and high free triiodothyronine (FT3, 2.20 pmol/L) and free thyroxine (FT4, 10.49 pmol/L) (Table 1). Multiple urinalyses indicated proteinuria (+ to +++). Multiple stool analyses were unremarkable. The patient was allergic to eggs, peanuts, and milk. Endoscopy (gastroscope and colonoscopy) found duodenal anterior wall erosion, and the immunohistochemical staining for cytomegalovirus (CMV) and *in situ* hybridization for EBV-encoded small RNA (EBER) were negative. Flow cytometry showed a slightly higher proportion of CD25+FOXP3+ Tregs in CD4+ T cells (13.0%) (Figure 2).

***Further diagnostic work-up***

The patient had early refractory diarrhea, malabsorption, high immunoglobulin E, hypothyroidism, and nephrotic syndrome. The diagnosis of IPEX was confirmed by whole exome sequencing, which revealed a pathogenic site in exon 5, c.542G>A (p.Ser181Asn) mutation of the *FOXP3* gene. Subsequently, the same heterozygous mutation was found in the mother, who was a carrier, but his father and older brother were normal (Figure 3). The family pedigree of the patient is shown in Figure 1.

**FINAL DIAGNOSIS**

The final diagnosis of the presented case was IPEX syndrome, hypothyroidism, and nephrotic syndrome.

**TREATMENT**

### The patient was initially diagnosed with refractory diarrhea, malabsorption, hypothyroidism, and nephrotic syndrome. He was treated with anti-infection medications, total parenteral nutrition, prednisone (5 mg/d), and euthyrox (37.5 µg/d). After 10 d of this treatment, he had 4–6 watery bowel movements per day but was not significantly gaining weight. Subsequently, the diagnosis of IPEX was confirmed by whole exome sequencing, and a scheduled immunosuppressor [treatment](file:///C:/Users/Administrator/AppData/Local/youdao/dict/Application/8.5.3.0/resultui/html/index.html#/javascript:;) was started. However, the family thought that these drugs had severe side effects and refused this type of treatment. Therefore, the patient was treated with prednisone, euthyrox, and other supportive cares.

**OUTCOME AND FOLLOW-UP**

Since the diagnosis of IPEX syndrome, the patient has been regularly treated with prednisone and euthyrox. Instead of getting better, his condition is slightly worse. He was hospitalized for refractory diarrhea (up to 15-20 watery bowel movements per day) and anasarca, and was discharged after correction of electrolyte disorder and dehydration therapy. At present, he is awaiting hematopoietic stem cell transplantation.

**DISCUSSION**

The typical symptoms of IPEX syndrome present as early refractory diarrhea, type 1 diabetes mellitus, and eczema[2]. The enteropathy of IPEX syndrome is present in virtually all affected individuals. The main manifestation of the patients was watery diarrhea and sometimes mucoid or bloody diarrhea[2]. Dermatitis is most frequently eczematous[6] and can also be psoriasiform[7] and ichthyosiform[8]. Endocrine diseases are common in type 1 diabetes mellitus, most of which are newborn[9], but hypothyroidism has also been reported[3]. Rare symptoms such as thrombocytopenia, hepatitis, pneumonia, and nephrotic syndrome have also been reported[3,10]{Torgerson, 2007 #70;Park, 2015 #67}. In this report, we present an early-onset IPEX syndrome case with chronic diarrhea as the first symptom at the age of 1 mo, as well as hypothyroidism and nephrotic syndrome. The patient received anti-infection therapy, total parenteral nutrition, and other supportive care more than five times after admission in 1 year. However, diarrhea was not well controlled. Finally, the patient was diagnosed with IPEX syndrome associated with a novel *FOXP3* gene mutation [c.542G>A (p.Ser181Asn)] by whole exome sequencing.

The human *FOXP3* gene is located on the X chromosome (Xq11.23–Xq13.3) and consists of 11 coding exons plus one upstream non-coding exon[11]. The gene encodes a protein of 431 amino acids, which contains a repressor domain, a zinc-finger (ZF) domain, a leucine zipper (LZ) domain, and a forkhead (FKH) domain (Figure 4). Ziegler *et al*[12] found that there were two functional domains within the N-terminal of FOXP3, one between amino acids 67 and 132 and the other between amino acids 135 and 198, which are functional as transcriptional repressors; the latter is especially required for inhibition of nuclear factor of activated T cells (NFAT)-mediated transcription. NFAT is an important transcription factor of cytokine gene expression. In the promoters of cytokine genes, it was found that the NFAT site potentially overlapped or was adjacent to the FKH-binding site[12]. Therefore, FOXP3 may play an immunosuppressive function by competing for the DNA-binding sites of NFAT or directly inhibiting the negative feedback of NFAT activity to regulate the expression of cytokine genes[13,14]. Therefore, this mutation leads to impaired NFAT transcriptional regulatory activity by altering the binding sites to DNA or inhibiting cytokine gene expression and eventually is responsible for this disease.

The *FOXP3* gene is a master regulator of Tregs[2]. If *FOXP3* mutation leads to this protein being functionally defective, it is unable to sustain Treg development[15]. Therefore, most IPEX patients had decreased percentages of CD25+FOXP3+ Tregs in CD4+ T cells. However, the patient had increased percentages in this study. In previous reports, in addition to the natural Treg cells in the thymus, peripheral CD4+CD25**－**cells can also develop into Tregs with inhibitory function by stimulation of anti-CD3 and anti-CD28[16] or by retroviral vector or transgene expression. Bacchetta *et al*[17] found that the ratio of CD4+CD25+ Tregs in peripheral blood mononuclear cells (PBMCs) can appear normal, but their capacity to suppress was impaired, which indicates that the *Foxp3* mutation could not affect Treg development but affected suppression function. Therefore, the function of *FOXP3* is not restricted to Tregs but it could also play a role outside the Treg subset. It has been reported in the literature that the percentage of CD4+CD25+ FOXP3+ Tregs in CD4+ T cells or the percentage of FOXP3 expressing CD4+ cells in children with IPEX is high (for example, mutation sites were p.M370I[18], p.E323K[19], and p.S390N[19]). Therefore, we speculate that the high ratio of CD25+ Tregs in our patient may be related to other regulatory factors.

**CONCLUSION**

IPEX is a rare X-lined recessive disease with multiple system involvement, especially enteropathy and refractory diarrhea, caused by mutations in the *FOXP3* gene. The onset of symptoms is as early as the first few months of life, and patients usually require supportive and alternative treatments. In the differential diagnosis of any patient with unexplained and intractable diarrhea, the disease should be considered and eventually confirmed by gene testing.

**REFERENCES**

1 **Bennett CL**, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* 2001; **27**: 20-21 [PMID: 11137993 DOI: 10.1038/83713]

2 **Barzaghi F**, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. *Front Immunol* 2012; **3**: 211 [PMID: 23060872 DOI: 10.3389/fimmu.2012.00211]

3 **Pogoriler J**, Kamin D, Goldsmith JD. Pediatric non-Helicobacter pylori atrophic gastritis: a case series. *Am J Surg Pathol* 2015; **39**: 786-792 [PMID: 25602795 DOI: 10.1097/PAS.0000000000000378]

4 **Chen CA**, Chung WC, Chiou YY, Yang YJ, Lin YC, Ochs HD, Shieh CC. Quantitative analysis of tissue inflammation and responses to treatment in immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, and review of literature. *J Microbiol Immunol Infect* 2016; **49**: 775-782 [PMID: 26748735 DOI: 10.1016/j.jmii.2015.10.015]

5 **Powell BR**, Buist NR, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. *J Pediatr* 1982; **100**: 731-737 [PMID: 7040622 DOI: 10.1016/s0022-3476(82)80573-8]

6 **Owen CJ**, Jennings CE, Imrie H, Lachaux A, Bridges NA, Cheetham TD, Pearce SH. Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. *J Clin Endocrinol Metab* 2003; **88**: 6034-6039 [PMID: 14671208 DOI: 10.1210/jc.2003-031080]

7 **Nieves DS**, Phipps RP, Pollock SJ, Ochs HD, Zhu Q, Scott GA, Ryan CK, Kobayashi I, Rossi TM, Goldsmith LA. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. *Arch Dermatol* 2004; **140**: 466-472 [PMID: 15096376 DOI: 10.1001/archderm.140.4.466]

8 **Baud O**, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, Dupuis-Girod S, Cerf-Bensussan N, Cavazzana-Calvo M, Brousse N, Fischer A, Casanova JL. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. *N Engl J Med* 2001; **344**: 1758-1762 [PMID: 11396442 DOI: 10.1056/NEJM200106073442304]

9 **Chatila TA**, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. *J Clin Invest* 2000; **106**: R75-R81 [PMID: 11120765 DOI: 10.1172/JCI11679]

10 **Park E**, Chang HJ, Shin JI, Lim BJ, Jeong HJ, Lee KB, Moon KC, Kang HG, Ha IS, Cheong HI. Familial IPEX syndrome: different glomerulopathy in two siblings. *Pediatr Int* 2015; **57**: e59-e61 [PMID: 25712815 DOI: 10.1111/ped.12570]

11 **Wildin RS**, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet* 2001; **27**: 18-20 [PMID: 11137992 DOI: 10.1038/83707]

12 **Ziegler SF**. FOXP3: of mice and men. *Annu Rev Immunol* 2006; **24**: 209-226 [PMID: 16551248 DOI: 10.1146/annurev.immunol.24.021605.090547]

13 **Schubert LA**, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. *J Biol Chem* 2001; **276**: 37672-37679 [PMID: 11483607 DOI: 10.1074/jbc.M104521200]

14 **Bettelli E**, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. *Proc Natl Acad Sci USA* 2005; **102**: 5138-5143 [PMID: 15790681 DOI: 10.1073/pnas.0501675102]

15 **Benoist C**, Mathis D. Treg cells, life history, and diversity. *Cold Spring Harb Perspect Biol* 2012; **4**: a007021 [PMID: 22952391 DOI: 10.1101/cshperspect.a007021]

16 **Walker MR**, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. *J Clin Invest* 2003; **112**: 1437-1443 [PMID: 14597769 DOI: 10.1172/JCI19441]

17 **Bacchetta R**, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C, Ziegler SF, Levings MK, Roncarolo MG. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. *J Clin Invest* 2006; **116**: 1713-1722 [PMID: 16741580 DOI: 10.1172/JCI25112]

18 **An YF**, Zhao XD, Xu F, Yang XQ. A noveI missense mutation of FoxP3 causes immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in a Chinese child. *Zhonghua Erke Zazhi* 2009; **47**: 824-828 [DOI: 10.3760/cma.j.issn.0578-1310.2009.11.007]

19 **Gambineri E**, Ciullini Mannurita S, Hagin D, Vignoli M, Anover-Sombke S, DeBoer S, Segundo GRS, Allenspach EJ, Favre C, Ochs HD, Torgerson TR. Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome. *Front Immunol* 2018; **9**: 2411 [PMID: 30443250 DOI: 10.3389/fimmu.2018.02411]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January **16, 2020**

**First decision:** March 5, 2020

**Article in press:**

**Specialty type:** medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ishizawa K **S-Editor:** Ma YJ **L-Editor:** Wang TQ **E-Editor:**

**Figure legends**

家系图谱最终版sci

**Figure 1 Family pedigree.** Theblack square and arrow indicate the patient, the point inside the circle indicates a heterozygous carrier of the gene, and white squares represent normal members in the family.

CD图片_最终版sci

**Figure 2 Flow cytometry showing CD25+FOXP3+ regulatory cells in the CD4+T cell population in peripheral blood.** The red number in each quadrant indicates the percentage of the individual. The percentages of CD25+FOXP3+T cells of the patient and his mother were not reducing (reference range 5.1%-12.7%).

基因测序最终版 sci 2

**Figure 3 The gene sequencing peaks of the two-generation family.** I (A) and II (A) indicate that no mutation was found; I (B) and II (B) indicate that the mutation site is c.542G> A.

FOXP3突变最终版sci22

**Figure 4 Schematic representation of the *FOXP3* gene and protein.** Numbers along the top line indicate amino acid number (1–431). The latter two lines refer to the gene structure, the coding and non-coding regions: N-terminal domain (orange), zinc-finger (ZF) domain (green), leucine-zipper (LZ) domain (blue), LZ-FKH loop (yellow), and FKH domain (red). The red arrows indicate the mutation site identified in this study.

**Table 1 Hematologic and immunologic data of the immune dysregulation, polyendocrinopthy, enteropathy, X-linked patient**

|  |  |  |  |
| --- | --- | --- | --- |
| **Blood index** | **Admission** | **Reference range** |  |
| WBC (× 109/L) | **23.25** | 3.5-9.5 |  |
| Eosinophils (× 109/L) | 0.13 | 0.02-0.52 |  |
| HGB (g/L) | 112 | 110-160 |  |
| ALB (g/L) | 29.1 | 40-55 |  |
| IgA (g/L) | 0.61 | 0.14-1.14 |  |
| IgG (g/L) | 9.12 | 3.82-10.58 |  |
| IgM (g/L) | 0.67 | 0.4-1.28 |  |
| IgE (IU/mL) | **1.970** | 0-60 |  |
| triglyceride (mmol/L) | **3.74** | 0.56-1.70 |  |
| complement C3 (g/L) | **0.25** | 0.8-1.5 |  |
| complement C4 (g/L) | **0.1** | 0.12-0.4 |  |
| TSH (mIU/L) | 0.931 | 0.38-7.31 |  |
| FT3 (pmol/L) | **2.20** | 4.1-7.42 |  |
| FT4 (pmol/L) | **10.49** | 14.45-22.74 |  |
| aTPO (U/ml) | 30.90 | < 60 |  |
| aTG (U/ml) | 20.50 | < 60 |  |

Abnormal values are shown in bold. WBC: white blood cells; HGB: hemoglobin concentration; ALB: albumin; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine; FT4: free thyroxine; aTPO: antithyroid peroxidase; aTG: antithyroglobulin.